Page 341 - Glucose Monitoring Devices

348 CHAPTER 16 The dawn of automated insulin delivery

type 1 diabetes. Diabetic Medicine: A Journal of the British Diabetic Association
2017;34(9):1228e34.
[4] Hagger V, Hendrieckx C, Sturt J, Skinner TC, Speight J. Diabetes distress among
adolescents with type 1 diabetes: a systematic review. Current Diabetes Reports
2016;16(1):9.
[5] Kadish AH. Automation control of blood sugar. I. A servomechanism for glucose
monitoring and control. The American Journal of Medical Electronics 1964;3:82e6.
[6] Clemens AH, Chang PH, Myers RW. The development of biostator, a glucose
controlled insulin infusion system (GCIIS). Hormone and Metabolic Research 1977;
(Suppl. 7):23e33.
[7] Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infu-
sion: an approach to achieving normoglycaemia. British Medical Journal 1978;
1(6107):204e7.
[8] Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma
glucose in juvenile diabetes by subcutaneous administration of insulin with a portable
infusion pump. New England Journal of Medicine 1979;300(11):573e8.
[9] Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, et al. Use of
insulin pump therapy in children and adolescents with type 1 diabetes and its impact
on metabolic control: comparison of results from three large, transatlantic paediatric
registries. Diabetologia 2016;59(1):87e91.
[10] Szypowska A, Schwandt A, Svensson J, Shalitin S, Cardona-Hernandez R,
Forsander G, et al. Insulin pump therapy in children with type 1 diabetes: analysis
of data from the SWEET registry. Pediatric Diabetes 2016;17(Suppl. 23):38e45.
[11] Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al.
Association of insulin pump therapy vs insulin injection therapy with severe hypogly-
cemia, ketoacidosis, and glycemic control among children, adolescents, and young
adults with type 1 diabetes. Journal of the American Medical Association 2017;
318(14):1358e66.
[12] Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al.
State of type 1 diabetes management and outcomes from the T1D exchange in
2016e2018. Diabetes Technology and Therapeutics 2019;21(2):66e72.
[13] Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al.
Continuous glucose monitoring and intensive treatment of type 1 diabetes. New
England Journal of Medicine 2008;359(14):1464e76.
[14] Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, et al.
REPLACE-BG: a randomized trial comparing continuous glucose monitoring with
and without routine blood glucose monitoring in adults with well-controlled type 1
diabetes. Diabetes Care 2017;40(4):538e45.
[15] FDA advisory panel votes to recommend non-adjunctive use of of Dexcom G5 mobile
CGM. Diabetes Technology and Therapeutics 2016;18(8):512e6.
[16] Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability
of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technology
and Therapeutics 2009;11(Suppl. 1):S113e9.
[17] Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream.
Diabetes Care 2015;38(6):1036e43.
[18] Elleri D, Allen JM, Nodale M, Wilinska ME, Acerini CL, Dunger DB, et al. Suspended
insulin infusion during overnight closed-loop glucose control in children and adoles-
cents with type 1 diabetes. Diabetic Medicine 2010;27(4):480e4.